

INVESTOR RELATIONS 2026

REMedi



Beyond 130 Years of X-ray Evolution

Smaller, Safer, Broader

DISCLAIMER

This material was prepared by Remedi (hereinafter referred to as the “Company”) for the purpose of providing information in a presentation to institutional investors in connection with the proposed IPO offering.

The “forecast information” included in this document consists of information that has not undergone individual verification procedures. This relates to matters concerning future events rather than the past, and refers to the company’s expected future management status and financial performance; in terms of expression, it includes words such as ‘expected,’ ‘outlook,’ ‘plan,’ ‘anticipation,’ and ‘(E).’

The above “forecast Information” is subject to change in the business environment and is inherently uncertain; therefore, due to this uncertainty, actual future performance may differ significantly from what is stated or implied in the “Forecast Information.”

In addition, the future outlook is based on the status as of the date of the presentation and takes into account current market conditions and the company's management direction; please be advised that it may be subject to change without prior notice due to future changes in the market environment or revisions to strategy.

Please be advised that the Company and its officers and employees shall not bear any liability for any losses arising in connection with the use of this material, including cases of negligence or other factors. Please be advised that this document does not constitute a solicitation for the offering, sale, trading, or subscription of shares, and that no part of this document may serve as a basis or ground for any related contracts, agreements, or investment decisions.

This material may be used for non-profit purposes without modification (provided that attribution is required), and please be aware that unauthorised distribution or reproduction of modified material without the company's prior approval may result in legal sanctions.



Conquering Infectious Diseases and Enabling POC Diagnosis
with Low-Dose, Compact X-ray Technology



Pioneering Space Exploration
with Low-Dose, Compact X-ray Technology



Innovating Quality Control on the Production Line
with Low-Dose, Compact X-ray Technology

TABLE OF CONTENTS

PROLOGUE

Chapter 01.
**COMPANY
OVERVIEW**

Chapter 02.
**CORE
COMPETENCIES**

Chapter 03.
**GROWTH
STRATEGY**

APPENDIX

01. Technological Limitations and Unmet Needs in the Market

Medical diagnostic and non-destructive testing technologies

REMEDI
 REVOLUTION IN MEDICAL DEVICES

Technical Limits



Large-scale and fixed equipment



Limited access to medical care leaves a significant portion of the global population **without adequate diagnostic imaging services.**
 Dedicated shielding facilities required, **resulting in higher installation and operating costs**



High radiation exposure



Increased radiation exposure poses risks to both patients and medical staff



Limitations of high-definition implementation



Large systems: Image degradation from increased scatter radiation
 Small systems: Heat-concentration issues limiting fine focal-spot performance

Addressing Global Unmet Needs in Medical and Industrial Sectors through Innovations in Low-Dose, High-Definition, and Compact Technology

Unmet Needs

Medical

Radiation hazards from high doses



The need for miniaturization technology




Large size	fixed type	High price
Shielded rooms are required	Additional personnel needed	Additional Costs Beyond Equipment

Non-destructive testing

The need for miniaturization technology

Large (limited by movement) / high dose / expensive / difficult operation



2,414x1,275x2,202 mm /
4,200kg


02. Market Paradigm Shift through Low-dose, Miniaturization Technologies

Innovation in access to Medical Imaging Diagnostics through Lightweight Design (About 2% Of Previous Levels)
and Low-dose (About 40% Of Previous Levels)


**Big****Heavy****Expensive**

Not easy to move
Require large spaces

Lead shielding facilities
are required
Patient and Worker
Radiation Safety




No need for lead shielding facilities
Patient exposure dose: 40% of
conventional products

Anywhere**Anytime****Everyone**

03. Remedi's Platform Technology and Global Product Lineup

Remedi's Platform Technology and Product Portfolio Simultaneously Realizing Low-dose, High Image Quality, and Miniaturization



Leading the Global X-ray Market with Remedi's Proprietary and Differentiated Technology

04. Who is 'REMEDI'

An X-ray Platform Company Transitioning from Technology Development to Global Market Expansion and Sustainable Revenue Generation

Remedi's Core Technology Competitiveness



14 Patents + Know-how

Low dose / High definition



4 Patents + Know-how

Small / Lightweight

- 10 key technologies + peripheral technologies + design and manufacturing technologies for core components and products of x-ray generators + system integration technologies
- Securing core technologies in low-dose, miniaturized x-ray and a robust global IP portfolio

Enabling Rapid Product Development "Across Diverse Industries"

Source technology

Securing proprietary low-dose, miniaturized x-ray technology and a robust global IP portfolio

Innovative products

Completion of full-stack product portfolio and commercialization across medical, industrial, and space sectors

Global Verification

Proven technology and commercial viability: validated by NASA and exports to over 50 countries

Market

Accelerating market penetration and expansion into medical, industrial, and space sectors, leveraging a global customer base targeting a 102 billion USD+ market

Finance

Achieved two consecutive years of operating profit: delivering both scalability and profitability

Chapter 01.

Company Introduction

- 01 Company Overview
- 02 Company History
- 03 Introduction to Key Products
- 04 Business performance

REMEDI



01. Company Overview


A Global Leader in Next-Generation X-ray Core Technology

Company Overview

Company Name	Remedi Inc.
Ceo	Bong-ho Cho
Date Of Establishment	July 13 , 2012
Capital	3.19 billion won
Employee	49 people
Headquarters Location	Sakju- ro, Chuncheon-si, Gangwon- do 145th Street 69-14, 2nd floor
Industry	Radiation device manufacturing
Website	https://remedihc.com/ko

Note : As of the end of 2025

Workplace location



Chuncheon Headquarters

- **location** Chuncheon City, Gangwon Province
145 Sakju -ro 69-14, 2nd floor
- **Main Product:** X- ray Generator
- **Production capacity** 3,700 units

Seoul R&D Center

- **location** Yangpyeong-ro, Yeongdeungpo-gu, Seoul 149
- **Key Business Areas:** R&D



Indian subsidiary

New Delhi Office

- **location** 8th Floor, Building No – 8, DLF Cyber City, DLF Ph-III, Gurgaon, Haryana

Bangalore Office

- **location** 2727, 3rd floor, Vanganhalli, Sector 1, HSR Layout, Bengaluru, Karnataka

Mumbai Office

- **location** 110 C Wing, Damji Shamji Corporate, Andheri Link Road, Laxmi Nagar, Ghatkopar East

Plans to establish additional overseas branches

02. Company History

Driving Commercial Growth through a Diverse Product Pipeline Built on Proprietary Low-Dose, Miniaturized X-ray Technology

From Technology to Market: Successfully Transitioning from R&D and Prototyping to Full-Scale Commercialization

2012

Technology development Securing and Advancing Core Technologies

- July 2012 Remedi Corporation Establishment
- April 2013 Establishment of a corporate research institute
- May 2015 Technology transfer of the world's first implantable intraoral radiation generator
- 2016 Launch of Portable X-ray Generator for Dental / Medical Use

low-dose / miniaturization technology

2017

Product development Application of source technology to products and completion of development

- September 2017 Portable x-ray generator ISO 9001, ISO 13485 certified and CE certified
- November 2017 Portable DR equipment, launch of oral camera equipment
- September 2018 Portable x-ray generator obtained US FDA certification
- June 2019 Interval secures investment (1.7 mil USD)
- February 2020 Dental imaging acquisition device (iods-2401, 2402) US FDA approval
- May 2020 Domestic product approval for medical portable x-ray generator (KA6)
- July 2020 LG electronics attracts investment (1.1 mil USD)
- July 2021 Ultra-small x-ray tube, KA6 CE certified
- August 2021 Medical x-ray generator (KA6) FDA certified
- October 2021 Portable dental x-ray obtains sales approval from the Japanese Ministry of Health, Labour and Welfare

2022

Commercialization Full-scale commercialization of core products

- February 2022 NANO-X IMAGING Secures Investment (0.8 Mil USD)
- June 2022 Recipient of the Korea Women Entrepreneur Award from the Minister of SMEs and Startups
- November 2022 REMEX-GR100 equipped with a micro X-ray tube, certified by the Ministry of Food and Drug Safety as a medical device.
- December 2022 Winner of the Grand Prize at the Innovation Procurement Competition
- September 2023 40 global startups by the G20 Summit
- November 2023 Establishment of Remedi India, an Indian subsidiary
- December 2023 Japan Ministry of Health, Labour and Welfare Selection of Products for Ukraine Procurement, Delivery
- 2024 Japan / Korea Xcam permission
- 2025 Innovation Premier 1,000 Company (Defense Industry Sector)
- July 2025 Legislation on the external use of portable X-ray equipment in Korea
- August 2025 Xcam6 US License



이레나 고문
창업자



박영일 CSO
기술경영



서현숙 CMO
의료기술



조성호 상무
부품/소재



노철호 부사장
제품/양산 기술




최태운 상무
생산



조봉호 대표이사
영업체계구축



권순용 CMO
의학전문인



Khusal Mehta
의사/MBA

10 elemental technologies
43 patents and know-how

6 industrial sectors, 33 Product Development
Radiation / Medical Device Licenses

5-Line Production System Established
KA6: 5 Years of 100% Annual Growth

03. Major business areas

Evolving from a Medical Device Manufacturer into an AI-Driven Personal Healthcare Platform

medical treatment

PHASE 01

Innovative products sales business

Portable series



PHASE 02

AX solution business

Lung disease package



- AI Automatic Reading Assistance
- Diagnostic Workflow Optimization
- SaaS-type integration software

expansion

Launch of various products

Mobile Replacement	C-arm Replacement	CT Replacement + Alpha	+++ Continuous development and launch
--------------------	-------------------	------------------------	---------------------------------------

Launch of various packages

Growth disorders	Fracture	Heart disease	+++ Continuous development and launch
------------------	----------	---------------	---------------------------------------

Industrial Non-Destructive Testing Business Division

RIX-B100


- Battery Inspection System Developed in Collaboration with LG Electronics
- Enabling Real-Time, Full-Scale Non-Destructive Testing (NDT) on Production Lines via Miniaturization



Parts Business Division


Emitter / Cathode / X-ray tube

Core Component of X-ray Generators



High Voltage Generator

Generating 50kV+ High Voltage to Power X-ray Tubes




04. Business performance

Achieving Rapid Revenue Growth Driven by Full-Scale Global Expansion


Revenue

Unit : Million Won




Operating Profit (Rate)

Unit : Million Won, %



Net Profit (Rate)

Unit : Million Won, %



Chapter 02.

Core Competitiveness

- 01 Platform Source Technology Competitiveness
- 02 Productization And Commercialization Capabilities of Source Technology
- 03 Competitiveness of Innovative Products
- 04 KA6 Product Specifications with Others
- 05 Representative Verification Reference of The International Community
- 06 KA6 Applications
- 07 Global Regulatory Status Global Expansion
- 08 Going Global

REMED



01. Platform Source Technology Competitiveness

Commercializing Innovative, Low-Dose, High-Definition Products by Leveraging Patented Core Technologies and Platform Expertise

14 Patents + Know - how

1. Low-dose , high-resolution X- ray generation technology	
LDX 01	LDX- based custom X- ray generator design protocol
LDX 02	Low-dose collimator design and control technology
LDX 03	Flat filter design and manufacturing technology
LDX 04	Digital control-based precision output control technology
LDX 05	Thermionic emitter digital control technology

4 Patents + Know - how

2. Lightweight and miniaturized X- ray generation technology	
MINIX 06	X- ray miniaturization technology based on ultra-high vacuum sealed process
MINIX 07	Ultra-compact high-voltage transformer design and control technology
MINIX 08	High-voltage arcing prevention and protection circuit technology
MINIX 09	X- ray driven optimized energy profiling technology
MINIX 10	Design and fabrication technology for small electron emitter and tubes

Peripheral technology

11	Shielding optimization technology
12	Video system design and Production technology
13	Radiation therapy system Design and manufacturing technology

**Key technologies + peripheral technologies + design and manufacturing technologies for core components
and products of x-ray generators + system integration technology**

**Agile innovation platform: optimizing 10 core low-dose & miniaturized technologies
to accelerate custom product development across diverse sectors**

02. Bridging Proprietary Technology to Commercial Success

Beyond R&D: Translating Core Technologies into Market-driven Solutions through Advanced Systems Engineering

Remedy products

2012 Low dose / Compact Technology development	2016	2020	2021	2022	2023	2024	2025	
								
	T100	KA6	RMT08/12	GR100	RIX B100	Xcam6	RIS-0506A	Xcam10
	(Dental / Medical)	(Medical)	(Tube)	(Dental)	Automobile battery for inspection	Medical (Chest)	Food inspection	Medical (whole body)
	Permits	Approved in 36 countries	19 countries	European CE	Korea / USA (3 countries)	US UL	Korea / Japan	Korea

Product	Process	Sales outlets
T100	Development started in 2015 → After launch in 2016 Licensed in 36 countries , 8,396 units sold cumulatively	74
KA6	Development started in 2020 → Domestic approval in 2020 → US FDA in 2021	46 pieces
RMT08/12	Development started in 2016 → CE 2021	4 pieces
GR100	Development started in 2020 → Domestic approval in 2021 → US FDA approval in 2024	Same as T100 retailer

Product	Process	Sales outlets
RIX-B100	Development started in 2020 → UL certification in 2023 → On sale	LG Electronics
Xcam6	Development started in 2023 → Domestic approval / Japanese approval in 2024 → US in 2025 Permit in progress	Same as KA6 retailers
RIS-0506A	Development started in 2025	Seoul National University
Xcam10	Development started in 2024 → Domestic licensing in progress in 2025	Same as KA6 retailers

03. Core Competitive Edge: Low-Dose, High-Definition, and Miniaturized Innovation

Proven Market Success: Leading Product Validated by Global Competitiveness and Scalability

Global Top Competitiveness REMEX-KA6 Advantages and Differentiators

Portability (Small)



- Compact and lightweight design allows for seamless imaging in any clinical environment
- Intuitive interface designed for rapid use during surgery and emergency procedures

Safety (Low dose)



- Minimizing radiation exposure for both patients and operators

High specifications (High Definition)



- Small focal spot size ensuring superior image clarity
- Capable of over 250 exposures on a single charge
- 12mAs tube current output, optimized for medical diagnostic requirements



REMEX-KA6
MEDICAL IMAGE SOLUTION

- Designated as an "Innovative Product" by the Ministry of SMEs and Startups ('21)
- Selected for the "MedTech Innovator 2024 Accelerator" (USA)
- Registered with UNGM (United Nations Global Marketplace) for international procurementGlobal Supply & Strategic Contracts
- NASA Supplier (Registered in US federal procurement system)
- Official supply contract with the Japanese Ministry of Foreign Affairs
- Recognized by WHO for TB (Tuberculosis) diagnostic technology
- Listed in the FIND (Foundation for Innovative New Diagnostics) directory
- Radiation/Medical device licenses secured or in progress in 23 countries
- Expanding global sales through a network of 46 key distributors
- Granted temporary regulatory approval for off-site medical use in Korea

04. KA6 Product Specifications with Others

KA6 is our leading product, a next-generation portable X-ray device, designed to deliver exceptional image quality with minimal radiation exposure in a compact, highly portable, and cost-effective form factor.

KA6 Product Specifications with Others

KA6 Product Specifications with Others		Remedi	Company M (USA)	Company F (Japan)	Comparison
		 KA6			Compared to other companies
Image quality Evaluation criteria	Tube voltage (kV)	40-90	40-90	50-90	Equal
	Tube current (mAs)	12	20	2.5	4.8 times higher
	Focal spot (mm)	0.4	0.8	0.8	2 times better
Convenience Evaluation criteria	Weight (kg)	2.4	7.4	3.5	1.45~3.1 times lighter
	Warm-up time (sec)	5	60	120	12~20 times faster
	Battery full charge time (hours)	1.1	3~4	4.5	3~4 times faster
	Battery usage count (times)	270-290	150	100	2 times Available


KA6 combines a high tube current and precision focal spot with an ultra-compact, lightweight frame, while offering significantly faster charging and superior usability for enhanced clinical workflows.

05. Representative Verification Reference of the International Community

Remedi's Competitiveness Proven in Various Overseas Markets Based on Innovative Technology

Selected for India Ministry of Health's medical infrastructure construction project

Secured a \$50M (68 Billion KRW) Infrastructure Project: Digitizing 2,301 Public Hospitals in India



[2,301 units currently being installed across India]

The first case of government-led product distribution nationwide

Supply to the Japanese Ministry of Foreign Affairs

Selected for the Japanese Government's Ukraine Support Project: KA6 Outperforms Domestic Competitors



Surpassing Japanese domestic products
Proving our product technology

NASA Stellar evaluation

Surpassing NASA's Rigorous Validation through Breakthroughs in Miniaturization and Low-Dose Innovation



a 200:1 competition ratio
Simultaneous verification of medical and non-destructive testing

Philippine Tuberculosis Association Operational Performance

Proven Durability in Extreme Environments: Over 1 Year of Continuous TB Screening (250+ Patients/Day at 46°C)



One-year operational analysis links to decrease d tuberculosis rates in the philippines

06. KA6 Applications

KA6's Versatility Empowering Diverse Point-of-Care (POC) Applications

Existing use within the hospital → Precision diagnosis

Intensive Care Unit

Operating room

Emergency room

Inpatient room

Orthopedics Outpatient Clinic

Pediatrics Outpatient Clinic



New Usage : Outside Hospital → Disease Triage

Ambulance /
emergency helicopter

Medical volunteer site


Eldery home care

Military unit

Battleground

Disaster site

Sports stadiums, etc.



07. Global Regulatory Status

Establishing a Foundation for Commercialization by Obtaining All Major National Licenses for Each Product Category

Domestic Business Licenses and Quality Certifications


Chuncheon business license	- Sales business registration certificate - Manufacturing license - Veterinary Medical Device Sales Business Registration Certificate - Radiation generating device production license
Seoul business license	- Radiation generating device sales permit - Permit for the use of radiation generating devices
Quality System	- GMP: Certificate of Conformity to Medical Device Manufacturing and Quality Management Standards - ISO13485 - Foreign Manufacturer Registration Certificate

Global Regulatory Status of Major Products

Item	Product Name	nation					
Medical portable	REMEX-KA6	korea	USA	EU	6 Southeast Asian countries	Two Middle Eastern countries	
		4 African countries		Two Latin American countries		Total 22 cases	
	ENDURO	USA					
	REMEX-Xcam6	korea	USA	EU	japan	Indonesia	Philippines
malaysia		Myanmar		Total of 8 cases			
Dental Portable	REMEX-T100 REMEX-K100 MobileX	korea	USA	EU	japan	Indonesia	6 Latin American countries
		5 Southeast Asian countries		10 Middle Eastern countries		4 African countries	Total 36 cases
	REMEX-GR100	korea	USA	EU	Ukraine		
Dental sensor	IoDS-2401 IoDS-2402	korea	USA	EU	Ukraine		Indonesia
		5 Southeast Asian countries		6 Middle Eastern countries		Two African countries	Total 20 cases
Mini tube	RMT-08	EU					
Non-destructive	RIX-B100	USA					
DET- Vieworks	REMEX RV-1417	USA					
	REMEX RV-1717						

08. Global Expansion

Proven Global Competitiveness across 45 Countries, Backed by Extensive Regulatory Credentials in Both Developed and Emerging Markets



Note : The number in parentheses next to the continent name indicates the number of dealerships.

Chapter 03.

Growth Strategy


- 01 Growth Roadmap
- 02 Business models in the medical field
- 03 Global Market Expansion Strategy in the Medical Sector
- 04 New upstream industries
- 05 New product development
- 06 Sales Forecast
- 07 Production Capacity Expansion Strategy
- 08 Mid-to-Long-Term Growth Vision _ Healthcare
- 09 Leaping forward as the global No. 1 mobile radiation solution company

REMED



01. Growth Roadmap

Driving Sustainable Growth through Platform-based Technology Innovation and Aggressive Global Market Expansion



02. Business Models in the Medical Field

Discovering New Target Markets through Product Diversification

Innovative Product Sales Business

Standalone product-focused sales model



AX solution business

AI- based
Expanding into a software-integrated business model

Package Solution



Customized Package Sales
X-ray Systems, Detectors, and Diagnostic AI

Pediatrics package	Orthopedics package	Internal medicine Package
Military unit package	Spinal surgery package	Home care package

POINT OF CARE MEDICAL DIAGNOSTIC SERVICES



AI- based personal health management service

03. Global Market Expansion Strategy in the Medical Sector

Phased Market Expansion: From Medical Infrastructure to Home Care Stepwise Global Expansion: From Emerging Markets to Developed Markets

Global Revenue Growth Roadmap

STEP 1 .

Verification of global references through small-batch multinational sales in 50 countries
 (Secured 218 cumulative global clients)

STEP 2 .

Focus on government and public healthcare infrastructure projects in key markets
 (India , Indonesia , Philippines , Bangladesh).

Full-Scale Public Infrastructure Projects in Four Established Asian Markets



India

- Additional Public Procurement Service 767 Order in 2026
- Social Insurance Corporation prepares bids for 0,000 units



Indonesia

- Ministry of Health and Welfare's mid-to long-term expansion plan targets 0,000 units



Philippines

- Government Orders for 2026
- Estimated quantity: 000 units



Bangladesh

- 2026 Ministry of Health and Welfare Preparing for 000 units bidding

Estimated 300,000 Clinic Members from Four Countries

→ Secures a Stable Revenue Base

STEP 3 .

Advanced markets (USA, Europe, etc) Home Care sector
 Entry into the Mobile Diagnostic Market

STEP 4 .

AI- based Mobile Diagnostic Services
 Personal Health Management Services

Market Entry Strategies


Key markets (India , Indonesia , Philippines , Bangladesh) Emerging markets (Africa , Middle East , CIS , South America)		Advanced markets (USA , Europe , Japan)	Market Dynamics
• Demand for expansion of medical infrastructure • Government-led large-scale projects • Large-scale demand		• Improvement of medical accessibility • From governments and international organizations	
KA6 / Xcam6 / Lung Disease AX Package		Xcam10 / AX Solution AX -based Mobile Diagnostic Service	Core Product
Expanding global distribution networks and partnerships based on Asian success stories		Entry into advanced markets based on innovative products	

04. New Upstream Industry (1) Non-Destructive Testing (NDT) Equipment for Secondary Batteries

Supplying Global Battery Production Lines with Proprietary 5.5kg Ultra-Lightweight, Low-Dose NDT Systems

Existing NDT equipment

- 4,200kg fixed equipment
- High dose → Installation space and movement constraints
- Sample testing



Remedi's NDT Solutions for Secondary Batteries

- 5.5kg ultra-lightweight
- Low dose → Can be installed on the production line
- Full inspection
(Final stage of the electrode process or stage before the packaging process)



Demonstration status

- US UL certification
- 13 sets (26 units) supplied
- Global battery companies conducting demonstration

Division	JV A	JV B	Factory C	JV D
Quantity	2 sets	2 sets	1 set	4 sets
location	Canada	Ohio	O-Chang	Michigan

Business feasibility

- Full inspection possible
- Recurring demand arises when production lines are expanded
- Securing recurring revenue through annual parts replacement

04. New Upstream Industries (2) The Space Industry

Proving Global Competitiveness by Being Selected as the Final Product Supplier amidst Competition among Korea, the U.S., And Japan

Selection Process of Remedi's Product by NASA

May 2024

Secured NASA Contracts
for Two Products
Amid 200:1 Competitive Ratio



June 2024 – December 2025

18-Month Rigorous Testing of 3 Products (Korea, Japan, USA)
in Extreme Space Environments at NASA Glenn Research Center

January 6, 2026

Xcam6 Selected as Final Supplier to NASA
Following Proven Technical Superiority



Medical treatment

Finger
Fracture
Diagnosis



Non-destructive testing

Extravehicular
Activity (EVA)
Spacesuit
Inspection



NDT of Shape
Memory Alloy
Rover Tires



04. New Upstream Industries (3) In-house Development and Commercialization of Core Components

Pioneering New Sales Channels through Proprietary X-ray Core Components

Tube Portfolio

Product Name	Product Image	Target specifications
RMT08		60kV/2mA, 13s [60W]
RMT12		70kV/3mA, 2s [210W]
RMT16		90kV/6mA, 2s [540W]
RMT18		100kV/10mA, 2s [1000W]
RMT23		120kV/12mA, 2s [14400W]

Tubes capable of small-batch mass production

RMT08 (For Non-Destructive Testing) /
RMT12 (For Dental sales)

Development completed tube


RMT18 (for KA6/Xcam6)

Tube under development

RMT23 (for Xcam 10)

Emitter · Tube

- Germany : Product Development for XRF (Ground Composition Analysis)
- Japan · China : Dental Sales
- USA : Carestream joint research proposal



High Voltage Generator

- US Listed Company NanoX :
Development (Appx. USD 0.4M), Sales,
and Investment Attraction (Appx. USD 1.06M)





High-voltage generator for low- cost CT imaging equipment

- Product development contract in 2020
Development completed in 2022
- Ready for mass production in 2022
- 153 units sold since 2022 (2025 : 30 units)


05. New product development

Driving Portfolio Diversification via Ongoing New Product Development in Targeted Sectors



06. Sales Forecast

Targeting Sustainable Revenue Growth through Phased Product Launches and Market Entry



07. Production Capacity Expansion Strategy

Expanding CAPA through Automated Production Lines to Meet Global Demand Achieving 40,000 Units Annual Production Capacity Upon Full Automation

Chuncheon : Plant 1

Start	2013	
Space	430 m ²	
Production	T100, KA6, etc.	
Permits	Medical device manufacturing license Radiation equipment production permit	
Maximum quantity	4,000 units / year	



Chuncheon : Plant 2

Start	2022	
Space	2,555 m ² (14 units)	
Production	T100, KA6, etc.	
Permits	Medical device manufacturing license Radiation equipment production permit	
Maximum quantity	43,200 units / year (When establishing automated production facilities)	


* Single Chamber Capacity: 7,700 Units per Year



08. Mid-to-Long-Term Growth Vision _ Healthcare

Securing Medical Data via HaaS and Scaling into SaaS Solutions

HaaS-based Data Acquisition (Medical Devices) → Data Accumulation → AI-powered SaaS Monetization



09. Leaping toward Becoming the Global No.1 Portable Radiation Solution Provider

Expanding Our Proprietary Platform Technology: From Medical to Industrial, and Finally, Aerospace Applications

Leading the global market in medical and non-destructive testing with compact, low-dose technology
that can go anywhere and see anything.

Medical treatment

Portable X- ray
AX Solution
Mobile Diagnostic

global
No. 1



Medical – Portable X- ray Leading
the global market

- Regulatory Approval and Sales Secured in 20 Countries
- Expanding linkages with global TB eradication projects
- Expanding for Tuberculosis + War Zones, Disaster Relief, and Home Care

Industry

Secondary battery inspection
Semiconductor inspection
Food inspection

global
No. 1



NDT – Market Entry

- World's First and Only Full-Inspection Solution for Secondary Batteries
- Food Inspection Systems
- Proven Track Record in Semiconductor Inspection

Universe

NASA
Space industry
National Defense

global
No. 1

